+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vectura Group Plc - Product Pipeline Analysis, 2022 Update

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Vectura Group Plc (Vectura) is a formulation, device design and development company. It focuses on the development of inhaled airways products through an integrated inhaled drug delivery platform. Its major products include dry powder inhalers (DPI) and metered dose inhalers (MDI) for patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) and other ailments. It offers formulation development, pharmaceutical analysis, device platforms, process development & technical transfer, product manufacturing and regulatory services. It has partnership and license agreements with global biotechnology and pharmaceutical companies to develop a portfolio of drugs, including inhaled in-market products and inhaled generics. Vectura is headquartered in Chippenham, Wiltshire, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Vectura Group Plc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Vectura Group Plc Company Overview
  • Vectura Group Plc Company Snapshot
  • Vectura Group Plc Pipeline Products and Ongoing Clinical Trials Overview
  • Vectura Group Plc - Pipeline Analysis Overview
  • Business Description
  • Vectura Group Plc - Key Fac

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aerogen Ltd
  • AstraZeneca Plc
  • Consort Medical Ltd
  • Inspiration Healthcare Group plc
  • Theravance Biopharma UK Ltd